Weingarten: #AACR18 PhIIB is expecting recipients to have substantial 3rd party funds.
5:30pm April 17th 2018 via Hootsuite
Weingarten: PhIIB bridge award is for 'crossing the valley of death'; tech validation, clin translation. $4M over 3y #AACR18
5:29pm April 17th 2018 via Hootsuite
Weingarten: STTR - from academia to small business. 23 institutes at the NIH. SBIRs are in 3 ph:PhI is $300K 6-12mo. PhII is $2M 2y #AACR18
Weingarten: Small Business Innovation Research setup in 1982; a set 3.0% in FY16 of the NCI extramural budget. FY17 3.2% $982M #AACR18
5:27pm April 17th 2018 via Hootsuite
Michael Weingarten (NCI SBIR): Translating cancer technologies from lab to market: success stories from the NCI SBIR program #AACR18
5:25pm April 17th 2018 via Hootsuite
Smith: #AACR18 Majority of clonotypes from one pt - quad clone, FLT3/NRAS/WT1/DNMT3A. Evidence for allele dropout of DNMT3A <10% ("triple
4:29pm April 17th 2018 via Hootsuite
Smith: #AACR18 Studying mech of relapse: 11/25 pts - 5 were oncogenic NRAS. Able to show clonal evolution, confer resist to gilteritinib
4:25pm April 17th 2018 via Hootsuite
Smith: #AACR18 Her work '17 https://t.co/SNFDypSfcp Goes onto ASP2215 active in-vitro againts refractory FLT3 mutant AML OS still relapse
4:22pm April 17th 2018 via Hootsuite
Smith: #AACR18 Around 20% are ITD, point mutations are another 5-10%. FLT3 KD mutations D835V/Y/F are common resistance mechanisms
4:17pm April 17th 2018 via Hootsuite
Smith: FLT3 is the most common mutated gene in AML; a receptor TK. Most common are internal tandem duplications in juxtamemb domain #AACR18
4:16pm April 17th 2018 via Hootsuite
MissionBio workshop con't: Catherine Smith (UCSF CA) Singel cell seq of polyclonal resistance to FLT3 inhibitors #AACR18
4:15pm April 17th 2018 via Hootsuite
Eastburn: #AACR18 Then PCR: amplicons produced. Access to gDNA restricted by chromatin. 19-gene AML panel 50 amplicons. 47 gene Myeloid
4:12pm April 17th 2018 via Hootsuite
Eastburn: #AACR18 Proteases digests histones, needs to be inactivated. Cell ID barcodes, PCR reagents, gene-spec primers added.
4:08pm April 17th 2018 via Hootsuite
Eastburn: #AACR18 Microfluidic cartridges: two-step workflow for cell encapsulation, barcoding. Cell lyste inside droplets, merge w/reagents
4:07pm April 17th 2018 via Hootsuite
Eastburn: #AACR18 Tapestri targets 300 loci, across 10k cells/sample. Enables sensitivity for rare clonal populations. Custom content
4:05pm April 17th 2018 via Hootsuite
Dennis Eastburn (MissionBio CA) #AACR18 Intro to technology: single-cell analysis can enable pt stratification, Rx selection, monitoring
4:04pm April 17th 2018 via Hootsuite
At the @nanostringtech booth #AACR18 nice to ‘see’ the VR demo of their new Digital Spatial Profiling instrument. H… https://t.co/05t5P9upob
4:01pm April 17th 2018 via Hootsuite
Dennis Li, Christina Alix-Panabieres, and Dolores Di Vizio at a Liquid Biopsy roundtable at #AACR18 https://t.co/nNnN8Dvm54
3:30pm April 17th 2018 via Hootsuite
Di Vizio: Mentions need for standardization, controls for EV studies. #AACR18
3:22pm April 17th 2018 via Hootsuite
Di Vizio: Mentions Apogoee/Nanostics for microflow cytometry to look at EVs from PSA levels in Pr Ca pts AUC of 0.84 #AACR18
3:19pm April 17th 2018 via Hootsuite
Di Vizio:Shows unpublished work of WGS of PrCa-derived EVs, and somatic CNVs, and then ddPCR for specific driver gene copy #'s #AACR18
3:14pm April 17th 2018 via Hootsuite
Di Vizio: Large EVs float to 1.10-1.15g/mL fx iodixanol centrifugation gradients. 'Std and ancient methods' https://t.co/t3T5nlKqt2 #AACR18
3:06pm April 17th 2018 via Hootsuite
Di Vizio: #AACR18 '12 Large oncosomes ref https://t.co/D9vQraltFi in mProstate Ca. >1um size, correlated with advanced disease
3:04pm April 17th 2018 via Hootsuite
Di Vizio: A huge need for standardization. '18 https://t.co/9vQs81RUl5 smallest 'exomere' 35nm! impt in cancer Large oncosomes #AACR18
3:03pm April 17th 2018 via Hootsuite
Di Vizio: '16 rev https://t.co/M6X1gHz6Oj EV's impt mediators of intercellular communication. Many types of EVs, affect target cells #AACR18
3:00pm April 17th 2018 via Hootsuite
Dolores Di Vizio (Cedars Sinai/UCLA CA) Cancer-derived extracellular vesicles and liquid biopsy: What have we learned? #AACR18
2:58pm April 17th 2018 via Hootsuite
A2: Lo: #AACR18 More biology - what's the clearance mechanism? A DNAse KO mouse - didn't change the profile of cfDNA size.
2:57pm April 17th 2018 via Hootsuite
Q: Moving to cancer screening, what else needs to be solved? Lo: #AACR18 Concentration so low, will need to look at many angles. (Holistic)
2:56pm April 17th 2018 via Hootsuite
Q: qPCR vs NGS? Lo: #AACR18 Their limit of det is 20 copies/mL for qPCR. If above that, will go onto NGS.
2:54pm April 17th 2018 via Hootsuite
Lo: #AACR18 PPV 2x the NEJM reported value (19.5%) with only 1x time point testing. Concl: EBV shows potential for early cancer screening
2:53pm April 17th 2018 via Hootsuite
Lo: #AACR18 Shows ability to do a training and test set, and can discriminate on both size of cfDNA and amount. Modeled back to 20K subjects
2:51pm April 17th 2018 via Hootsuite
Lo: #AACR18 Deletions of entire p arm, ampl of entire q arm, will affect size distribution as well.
2:48pm April 17th 2018 via Hootsuite
Lo: #AACR18 Shows fig from '10 STM https://t.co/ppV6VTqPvp fetal cfDNA has 20bp difference, two turns of the helix
2:46pm April 17th 2018 via Hootsuite
Lo: #AACR18 Logistics: 4w pause between tests, individuals may get worried. Lays out plan to do a 2-in-1 method (asked not to post)
2:43pm April 17th 2018 via Hootsuite
Lo: #AACR18 Older - higher risk. Temp of the day blood collected (!) Lower temp - higher FP rate. 'Summer rate 1/2 of winter'
2:40pm April 17th 2018 via Hootsuite
Lo: #AACR18 Their NEJM paper '17 https://t.co/mH9TxfYT5w 50 EBV copies/cell. FP's is likely due to viral re-activation. Predisposition?
2:39pm April 17th 2018 via Hootsuite
Lo: #AACR18 Able to get PPV of 11%. 75% of individ III/IV. NPC ID'd by screening. PFS hazard ratio improved 10x
2:38pm April 17th 2018 via Hootsuite
Lo: #AACR18 Could reduce FP rate, nasal endoscopy and MRI. Weekly commun. visits, 200 indiv/week. 20,174 subjects, 5.5% pos, 1.5% double pos
Lo: #AACR18 cfDNA is an archetype - to answer early detection question. Plasma EBV: at beginning everyone tested for EBV. If + retest in 4w
2:36pm April 17th 2018 via Hootsuite
Lo: #AACR18 cfDNA has a half-life of 4d. After surgery - 1.5h Clin monitoring - reflect what happens to tumor.
2:35pm April 17th 2018 via Hootsuite
Lo: 1:39 risk of NPC (Nasopharyngeal Cancer) among southern Chinese. EBV in the blood - '99 https://t.co/Sn1NMeh1DA #AACR18
2:33pm April 17th 2018 via Hootsuite
Y. M. Dennis Lo (Univ HK) "Towards cancer screening using circulating DNA" #AACR18
2:31pm April 17th 2018 via Hootsuite
Alix-Panabieres: #AACR18 Program in 2w: https://t.co/LrbDyQfp1H and two post-docs open.
2:28pm April 17th 2018 via Hootsuite
Alix-Panabieres: #AACR18 (Shows unpublished data.) Other circulating, complementary info from ctDNA, cfmiRNA, exosomes. CANCER-ID
2:27pm April 17th 2018 via Hootsuite
Alix-Panabieres: #AACR18 No spec morphology to initiate metastasis Shows hierarchical clustering of 9 lines; they differ
2:24pm April 17th 2018 via Hootsuite
Alix-Panabieres: Need at least 300 CellSearch cells, to get cells to grow. Many events to get a rare event for metastatic seeding #AACR18
2:23pm April 17th 2018 via Hootsuite
Alix-Panabieres: Their CTC-derived line was stable now for 5y. '17 https://t.co/gvimww5DOq a 'molecular portrait' Spec transcription #AACR18
2:22pm April 17th 2018 via Hootsuite
Alix-Panabieres: Capture of CTCs from colon cancer pts from their liver '15 https://t.co/A5wWJNMQPd Phenotypes, scRNA-seq #AACR18
2:20pm April 17th 2018 via Hootsuite
Alix-Panabieres: #AACR18 First to culture CTCs https://t.co/mP2y6a8X2W won an #AACR17 award for this work.
2:19pm April 17th 2018 via Hootsuite
Alix-Panabieres: #AACR18 Points to this '14 Lancet Oncol paper https://t.co/fxnm2ErCR4 regarding clinical validity of CTC
2:18pm April 17th 2018 via Hootsuite
